Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics: policy needs for personal prescribing.

David Melzer1, Ann Raven, Tom Ling

  • 1Department of Public Health and Primary Care, University of Cambridge, Cambridge CB2 2SR, UK.

Journal of Health Services Research & Policy
|January 26, 2005
PubMed
Summary

Pharmacogenetics uses genetic testing to personalize drug therapy, aiming for improved safety and effectiveness. However, policy actions are crucial to ensure evidence-based implementation and avoid potential patient harm and unequal access to treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chondrocalcinosis and the haemochromatosis-linked <i>HFE</i> C282Y homozygous variant in the UK Biobank.

EULAR rheumatology open·2026
Same author

Imagining Genomics and Population Health in 2050: Anticipating Future Research, Policy, and Governance Needs.

Public health genomics·2026
Same author

Predictors of MRI-estimated brain iron deposition in dementia and Parkinson's disease-associated subcortical regions: Genetic and observational analysis in UK Biobank.

Journal of Alzheimer's disease : JAD·2025
Same author

Reframing the evaluation of integrated care; examples from the NHS in England.

Health policy (Amsterdam, Netherlands)·2025
Same author

A systematic analysis of the contribution of genetics to multimorbidity and comparisons with primary care data.

EBioMedicine·2025
Same author

Mitochondrial DNA copy number associated dementia risk by somatic mutations and frailty.

GeroScience·2024

Area of Science:

  • Pharmacogenetics and its impact on drug development and clinical practice.
  • Translational genomics and personalized medicine.

Background:

  • Pharmacogenetics, the study of genetic variations influencing drug response, promises enhanced drug safety and efficacy.
  • Current understanding of the pharmacogenetics science base and clinical application emergence remains uncertain.
  • Existing commentary often overlooks older drugs, which are responsible for most adverse drug events.

Purpose of the Study:

  • To evaluate the potential benefits and policy challenges associated with pharmacogenetics in drug treatment.
  • To highlight the need for robust evidence and regulatory frameworks for pharmacogenetic tests and applications.
  • To address concerns regarding the integration of pharmacogenetics into routine clinical practice and health policy.

Main Methods:

Related Experiment Videos

  • Review of current literature and commentary on pharmacogenetics.
  • Analysis of regulatory differences between the USA and Europe regarding genetic testing.
  • Discussion of requirements for clinical decision-making, post-marketing surveillance, and health records.

Main Results:

  • The science base and clinical application rate of pharmacogenetics are currently uncertain.
  • Regulatory approaches to genetic tests differ significantly between the USA and Europe.
  • Integration into clinical practice requires computer-based health records and decision support systems.

Conclusions:

  • Urgent health policy action is needed to guide the development and implementation of pharmacogenetics.
  • Without proper oversight, pharmacogenetics may lead to poorly evaluated tests, increased costs, and patient risks.
  • Ensuring equitable access to evidence-based pharmacogenetic treatments is essential to avoid excluding patient groups.